In November 2025, the Staff of the Securities and Exchange Commission (SEC) announced that, for the 2026 proxy season, with one narrow exception, ...
CS2009 was designed to restore T-cell effector function, remodel the tumor microenvironment (TME), and enhance T-cell priming via simultaneous targeting of PD-1, VEGF, and CTLA-4, aiming to generate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results